Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Healthcare experts examine potential cost savings in maternal mortality reduction, adolescent cancer treatment, and biosimilar medication use. Studies reveal the importance of long-term financing plans and access to follow-up care for improved outcomes.
Scientists at EPFL introduce a novel biosensor molecule that can quickly measure drug concentration in patients' systems using a digital camera. The method is simple, low-cost, and can be used by patients themselves.
Researchers found that early palliative support services significantly reduced depression and feelings of overwhelm among family caregivers, improving overall quality of life. The study suggests that timely intervention can better equip caregivers to cope with the demands of caring for patients with advanced cancer.
Researchers at Mayo Clinic have demonstrated a potential delivery vehicle for brain cancer chemotherapy drugs, enabling the transport of eight different molecules across the blood-brain barrier. The breakthrough method mimics a normal physiological process and could aid in evaluation of new drugs for brain cancer treatment.
Researchers develop new computational method to design novel protein nanostructures, including cage-like proteins with symmetrical architectures. These structures may be used to deliver cancer drugs directly to tumor cells, sparing healthy cells.
The American Society of Clinical Oncology recognizes MD Anderson leaders Gabriel Hortobagyi, Waun Ki Hong, and John Mendelsohn for their significant contributions to cancer research. Mendelsohn is known for his discovery of the monoclonal antibody Erbitux, while Hong has made groundbreaking advances in treating head and neck cancers.
A study found that approximately 25% of children with acute lymphocytic leukemia (ALL) are missing too many doses of essential maintenance medication, which minimizes the risk of relapse. Nonadherence triples relapse risk, with African Americans and Asians being more prone to non-adherence than non-Hispanic whites.
The DREAM project has successfully mined genomic data to predict breast cancer cell line responses to drugs, achieving 78% accuracy in identifying sensitive versus resistant cell lines. The study also identified molecular markers that can be tested against large collections of human samples.
A phase 1b immunotherapy trial combining nivolumab and ipilimumab has shown high one-year and two-year overall survival rates of 94% and 88%, respectively, in advanced melanoma patients. The treatment regimen has demonstrated long-lasting benefits for these patients.
Research confirms BRCA2 gene mutations increase lung cancer risk by 1.8 times in smokers and double the risk for some individuals. The study also identified associations with CHEK2 and TP63 genes, highlighting potential targets for early screening and treatment.
A Phase III clinical trial found that enzalutamide significantly reduced the risk of prostate cancer progression by 81 percent and improved overall survival by 29 percent. The treatment also helped prevent cancer spread to bones and delayed chemotherapy needs.
A preclinical study of Rice University's quadrapeutics technology found that it can detect and kill cancer cells instantly, without harming surrounding normal organs. The technology uses a combination of existing clinical treatments and mechanical events triggered by nano-explosions to target cancer cells.
Researchers used gene expression arrays to analyze biopsies from ICON7 patients and found that patients with proliferative and mesenchymal subtypes responded best to bevacizumab. This subtype analysis may help identify patients who will benefit from the treatment, potentially reducing unnecessary toxicity.
A new trial found that giving chemotherapy immediately to men with newly diagnosed, hormone-sensitive prostate cancer can extend their survival by more than a year. The study showed significant benefits in both overall and high-extent disease populations.
Researchers at Mount Sinai present promising findings on innovative treatments for recurrent ovarian cancer, molecular profiling of bile duct and gallbladder cancers, and adjuvant therapy for melanoma. The studies demonstrate encouraging results for patients with these rare and often fatal diseases.
Researchers have found that crizotinib produces significant responses in patients with intermediate and high MET amplification, resulting in a 60-67% overall objective response rate. The drug showed early activity against MET-dependent cells in preclinical laboratory studies.
OMP-54F28, a Wnt inhibitor targeting cancer stem cells, has shown promising results in a Phase I clinical trial. The drug was generally well-tolerated and resulted in stable disease for over six months in several patients with advanced solid tumors.
A University of Colorado Cancer Center study found NTRK1 mutations in over 1% of non-small cell lung cancer patients. The study also developed a test for rapid detection of NTRK1 oncogenes, marking a new frontier in lung cancer treatment.
Researchers presented promising results from four clinical trials featuring new targeted drugs for advanced ovarian, lung and thyroid cancers, as well as chronic lymphocytic leukemia. These treatments showed potential to slow disease progression and improve survival rates for patients with relapses or treatment resistance.
Researchers report promising results from a phase I study on MPDL3280A, an investigational drug for treating advanced bladder cancer. The trial showed improved response rates among patients with PD-L1-positive tumors, with 7% achieving complete responses.
A phase 3 study found that ibrutinib significantly lengthened progression-free survival as a second-line therapy for CLL, with 86% of patients on ibrutinib experiencing durable responses. Ibrutinib also showed superior results compared to ofatumumab in terms of overall survival and partial response rates.
The American Society for Clinical Oncology has released new clinical guidelines for cancer-related fatigue, developed in collaboration with Moffitt Cancer Center. The guidelines recommend regular screening and treatment of fatigue in cancer patients after treatment, as well as addressing other contributing factors such as depression, p...
Jackson Laboratory Assistant Professors Jennifer Trowbridge and Chengkai Dai have received federal research grants to investigate acute myeloid leukemia and metformin's anti-cancer effects. They aim to elucidate specific problems in key areas of cancer research.
Researchers found that discontinuing statins in patients with advanced illnesses resulted in improved overall quality of life and lower costs without increased deaths. Patients who stopped taking statins appeared to live slightly longer, with median survival times of 229 days compared to 190 days for those continuing the drug.
A new study found that prostate cancer patients who underwent external beam radiation therapy were 70% more likely to develop rectal cancer and 40% more likely for bladder cancer. Survivors should be aware of symptoms such as pelvic pain, difficulty urinating, or blood in stool to monitor for potential secondary cancers.
The investigational agent DMOT4039A, a combination of chemotherapeutic agent and antibody, showed initial evidence of anti-cancer activity in a phase I clinical trial for pancreatic and ovarian cancers. The drug targets mesothelin-rich cancer cells, reducing the risk of off-target effects.
Researchers at the University of California, San Diego School of Medicine have identified two gene mutations that cause uveal melanoma, a type of eye cancer. They also found that an existing FDA-approved drug can slow tumor growth in experiments with mice.
Researchers at the University of Montreal have discovered a novel mechanism of drug resistance in leukemia and other cancers, which is driven by overactivity of the GLI1 gene. The team has identified drugs that can inhibit this gene's activity, potentially switching cancer cells back into sensitivity to existing chemotherapy.
Researchers have developed nanoscale structures called 'nanodaisies' that can deliver multiple anti-cancer drugs to cancer cells. These daisy-shaped structures show promise in treating lung, leukemia, breast, prostate, liver, ovarian and brain cancers.
Researchers have created an innovative 3D test system that allows them to simulate human body functions, enabling the development of more effective cancer treatments. The artificial lung model, no bigger than a sugar cube, can be used to analyze treatment resistance and metastasis formation, potentially leading to personalized medicine.
Cancer cells utilize a protein called Aiolos, which allows them to acquire blood cell characteristics and spread throughout the body. Researchers have discovered how this mechanism works, offering hope for future treatments.
Scientists have identified two genes, MLF2 and RPL39, that may affect the most lethal type of breast cancer. Suppressing these genes can reduce tumor formation and metastasis by interfering with blood vessel formation and recruitment.
Researchers at Yale Cancer Center presented findings from the 50th Annual Meeting of ASCO, highlighting the effectiveness of nivolumab and ipilimumab in treating advanced melanoma. Additionally, studies showed that lifestyle changes such as healthy eating and regular exercise can decrease biomarkers related to breast cancer recurrence ...
A phase I study found that alisertib inhibited aurora A kinase, a target for aggressive lymphoma treatment, in about one-third of patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. The oral drug showed manageable side effects, paving the way for advanced trials.
A new centre, The Oxford Centre for Drug Delivery Devices (OxCD3), will be established to exploit engineering approaches to improve the therapeutic outcomes of drug-based cancer treatments. The centre aims to use stimulus-responsive nanocarriers and medical devices to enhance drug delivery into tumours.
Researchers at UC Berkeley have discovered the mechanism by which Taxol interferes with microtubule polymerization, preventing cell division in cancer cells. This finding could lead to the development of better anticancer drugs and improvements to existing treatments.
Researchers have successfully blocked autophagy in a range of aggressive cancers, including glioblastoma, melanoma, and myeloma, using hydroxychloroquine. The study shows that combining autophagy inhibitors with other cancer therapies can be safe and effective for patients with very sick cancers.
Researchers from VTT Technical Research Centre of Finland discover a new anticancer compound, Cent-1, that kills cancer cells through a similar mechanism to Rigosertib. This breakthrough uses computer-assisted screening and cell-based assays to accelerate drug discovery and potentially lower development costs.
Researchers used computer simulations to identify most effective drugs for brain cancer, considering genomic signatures and predicted sensitivities. The approach may help personalize therapies for cancer patients, selectively testing effective drugs while reducing exposure to toxic ones.
A team of researchers created a database called K-Map that allows scientists to reposition existing drugs to treat various types of cancer. The database enables the evaluation of rational drugs and drug combinations, leading to new potential treatments such as bosutinib for non-small cell lung cancer.
Researchers at Penn State have identified a pine bark substance, leelamine, that can simultaneously target multiple protein pathways in melanoma cells, shutting down their survival communication and leading to cell death. This unique approach may address the issue of resistance to current melanoma drugs.
Chemists at Scripps Research Institute have determined the correct structure of TIC10, a promising anticancer compound approved by FDA for clinical trials. The correct structure differs from an earlier published version and describes a molecule with potent anticancer effects in animals.
The Gordon Sondland and Katherine Durant Foundation has donated $1 million to the Oregon Health & Science University's Knight Cancer Institute to establish an annual research conference, drawing top thought leaders in cancer treatment. The conference aims to accelerate breakthroughs in early detection and treatment.
Cancer research calls on institutions to increase Hispanic patient enrollment, highlighting health disparities and underrepresentation in clinical trials. The study emphasizes the need for adequate representation to ensure effective treatment and reduce disparities.
Scientists used neutron scattering techniques to study mAb clustering, revealing extended clusters in high-viscosity solutions. The insights could help design devices for delivering biopharmaceuticals at high concentrations.
The University of Louisville has received a three-year, $5.5 million grant from the Leona M. and Harry B. Helmsley Charitable Trust to develop new treatments and vaccines for various forms of cancer. Researchers will focus on plant-based pharmaceuticals and vaccines for cervical and colon cancer.
Dr. Neal Meropol, Chief of Hematology and Oncology at Case Western Reserve University, is honored as an ASCO Fellow for his exceptional volunteer service and dedication to cancer care. He has served on the ASCO Board of Directors and various committees, contributing to the organization's mission to improve cancer care.
Researchers are testing whether therapy incorporating advanced genomic technology will provide better outcomes than current treatments for women with an aggressive form of breast cancer. The trial uses targeted DNA sequencing to identify specific treatment choices that improve survival rates.
Researchers developed a new technology that can generate visible light deep within the body, activating drugs and destroying tumors. This approach could greatly expand photodynamic therapy's effectiveness, offering fewer side effects and precise targeting of cancer cells.
Researchers found that PLX3397, a tyrosine kinase inhibitor, induced partial responses and stable disease in 79% of evaluable patients with advanced PVNS. The drug demonstrated significant tumor size reduction and minimal side effects.
A team of USC and NYU researchers has developed a small molecule that interferes with cancer progression by mimicking the surface topography of one protein, tricking another into binding with it. This stops an aberrant gene expression contributing to cancer growth with minimal side effects.
The University of Chicago Medicine Comprehensive Cancer Center has been awarded a five-year, $3.9-million grant to serve as a Lead Academic Participating Site for the National Clinical Trials Network. The new network aims to improve cancer clinical trials' speed and efficiency.
A new study reveals that US cervical cancer rates are higher than previously believed, particularly among women over 65 and African-American women. The study found an age-standardized rate of 18.6 cases of cervical cancer per 100,000 women, with incidence increasing steadily with age.
Researchers developed a novel anti-cancer drug delivery method using lipid-based nanocapsules to deliver drugs directly to cancer cells. The technique triggers the release of the drug, leading to cell death in breast cancer tumors. This efficient and fast-acting approach may improve treatment outcomes for cancer patients.
Researchers at Dartmouth's Norris Cotton Cancer Center have discovered a new epigenetic mechanism that distinguishes normal blood stem cells from blood cancers. This finding holds promise for developing targeted treatments that preserve healthy stem cells while killing leukemia cells.
Researchers develop nanoparticles that release two chemotherapy drugs, erlotinib and doxorubicin, at staggered times to weaken tumor cells' defenses before delivering DNA-damage. This approach dramatically shrinks lung and breast tumors in mice, including aggressive triple-negative breast cancer cells.
Using a novel bioinformatics approach, researchers have found that the approved antimicrobial drug pentamidine may help treat advanced kidney cancer. The study identified gene expression patterns that suggest an antimicrobial may be effective against clear cell renal cancer, a common and highly malignant subtype of kidney cancer.
Two UT Southwestern doctors have received grants to test the effectiveness of itraconazole on lung cancer pathways and growth. The researchers aim to disrupt communication between tumor cells and their surrounding environment, slowing cancer growth.
Researchers discovered microRNA-10a regulates human airway smooth muscle cell growth and inhibits PI3 kinase, a master regulator of cell proliferation. This finding offers a new approach to treating both asthma-induced muscle thickening and cancerous tumor growth.
Researchers have identified a key chemical that can repair damaged cell nuclei, a breakthrough in treating Hutchinson-Gilford Progeria Syndrome (HGPS), a rare and devastating ageing disease. The compound, Remodelin, also shows promise in reducing DNA damage and improving cellular health.